stockrowBillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) EV/Sales
As of 5 November 2026, BillionToOne, Inc. (BLLN) trades at a EV/Sales of 11.0×. Over the past ten years it has ranged from 1.9× (March 2026) to 16.4× (August 2026); the current reading is higher than 76% of that period. That is above the Diagnostics & Research industry median of 5.2× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.8× | (29.93%) |
| FY2024 | 4.0× | 0.00% |
| FY2023 | 4.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 10.4× | (18.84%) |
| Jun 2026 | 12.9× | 43.41% |
| Mar 2026 | 9.0× | 217.79% |
| Dec 2025 | 2.8× | (29.93%) |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VCYT Veracyte, Inc. compare | 2.5× |
| RDNT RadNet, Inc. compare | 3.0× |
| NEO NeoGenomics, Inc. compare | 3.3× |
| SHC Sotera Health Company compare | 5.2× |
| QGEN QIAGEN N.V. compare | 5.4× |
| CDNA CareDx, Inc. compare | 7.6× |
| BLLN BillionToOne, Inc. | 11.0× |
| ADPT Adaptive Biotechnologies Corporation compare | 14.6× |
| GRAL GRAIL, Inc. compare | 29.8× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on BLLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement